摘要
Abstract
Objective Literature review meta-analysis and cost-effectiveness analysis on standard chemotherapy plus bevacizumab in metastatic colorectal cancer(mCRC)to explore the efficacy,safety and cost-effectiveness on the addition of bevacizumab.Methods To Search meta-analysis and cost-effectiveness analysis of chemotherapy plus bevacizumab on databases,such as MEDLINE,PubMed,CNKI chemotherapy.Results Six included analyses indicate that chemotherapy plus bevacizumab significantly prolonged progression-free survival(PFS)and overal survival(OS).The risk of hypertension,bleeding and proteinuria are significantly increased,whereas there are no significant differences on gastric perforation,thrombosis. Eleven cost-effectiveness analysis demonstrate that the addition of bevacizumab lead to higher medical cost and healthcare cost. In most countries involved in this review,chemotherapy plus bevacizumab is not cost-effective comparing with standard chemotherapy. However,the medical and healthcare cost of using bevacizumab is lower than cetuximab.Conclusion The addition of bevacizumab significantly increases survival benefits and slightly leads to more adverse events.Due to higher cost of bevacizumab,it is not cost-effective therapy for mCRC patients. According to the potential considerable differences on economic status,epidemiology,clinical efectiveness,the generalizability of included meta-analyses and cost-efectiveness analyses need to be taken into account. Analyses based on China local data should be done in the future.关键词
贝伐珠单抗/转移性结直肠癌/成本效果/研究Key words
Bevacizumab/Metastatic colorectal cancer/Cost-effectiveness/Research分类
医药卫生
